Padsevonil (DrugBank: Padsevonil)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 149 | 片側痙攣・片麻痺・てんかん症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194958 | 01/10/2019 | 18/09/2019 | A pharmacokinetic, safety, and tolerability study of padsevonil in CYP2C19 genotyped healthy male Japanese study participants. | An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants | Epilepsy and epilepsy syndrome | Intervention name : padsevonil INN of the intervention : padsevonil Dosage And administration of the intervention : Oral administration Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | complete | 20 | 55 | Male | 39 | Phase 1 | Japan |